Market capitalization | $682.32m |
Enterprise Value | $565.11m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.11 |
P/S ratio (TTM) P/S ratio | 6.17 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 202.25% |
Revenue (TTM) Revenue | $110.50m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
9 Analysts have issued a Wave Life Sciences Ltd. forecast:
9 Analysts have issued a Wave Life Sciences Ltd. forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -58 -58 |
64%
64%
|
|
Depreciation and Amortization | 9.21 9.21 |
9%
9%
|
|
Stock Compensation | 9.80 9.80 |
43%
43%
|
|
Operating Cash Flow | -19 -19 |
85%
85%
|
|
Investments | 1.12 1.12 |
18%
18%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -21 -21 |
84%
84%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
Head office | Singapore |
CEO | Paul Bolno |
Employees | 268 |
Founded | 2012 |
Website | www.wavelifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.